Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China

被引：0
|
作者：
Haijing Guan
Yanan Sheng
Wanjie Guo
Sheng Han
Luwen Shi
机构：
[1] Peking University,School of Pharmaceutical Sciences
[2] Peking University,China Center for Health Economic Research
[3] Peking University,International Research Center for Medicinal Administration
来源：
Advances in Therapy | 2019年 / 36卷
关键词：
Alectinib; ALK; China; Cost-effectiveness; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1114 / 1125
页数：11
相关论文
共 50 条
  • [1] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    [J]. ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [2] Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    [J]. ADVANCES IN THERAPY, 2020, 37 (02) : 971 - 972
  • [3] Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
    Haijing Guan
    Yanan Sheng
    Wanjie Guo
    Sheng Han
    Luwen Shi
    [J]. Advances in Therapy, 2020, 37 : 971 - 972
  • [4] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Mu, Lifeng
    Zhou, Benhong
    [J]. ADVANCES IN THERAPY, 2020, 37 (02) : 968 - 970
  • [5] Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
    Lifeng Mu
    Benhong Zhou
    [J]. Advances in Therapy, 2020, 37 : 968 - 970
  • [6] COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY UNTREATED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
    Xie, J.
    Knoll, S.
    Slowley, A.
    Bensimon, A.
    Vieira, J.
    Chilcott, J.
    Paisley, S.
    Zhou, Z.
    [J]. VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [7] Cost-effectiveness of ceritinib in previously untreated ALK-positive advanced non-small cell lung cancer in Hong Kong
    Loong, H. H.
    Wong, C. K. H.
    Leung, L. K. S.
    Chan, C. P. K.
    Chang, A.
    Gibbs, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [8] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [9] COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Guler, B.
    Orfanos, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S40 - S40
  • [10] Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
    Peters, Solange
    Camidge, D. Ross
    Shaw, Alice T.
    Gadgeel, Shirish
    Ahn, Jin S.
    Kim, Dong-Wan
    Ou, Sai-Hong I.
    Perol, Maurice
    Dziadziuszko, Rafal
    Rosell, Rafael
    Zeaiter, Ali
    Mitry, Emmanuel
    Golding, Sophie
    Balas, Bogdana
    Noe, Johannes
    Morcos, Peter N.
    Mok, Tony
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 829 - 838
12345